The FDA Has Bridgebio Pharma's New Drug Application For Acoramidis For Transthyretin Amyloid Cardiomyopathy, With An Action Date Of November 29
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted BridgeBio Pharma's New Drug Application for Acoramidis for the treatment of Transthyretin Amyloid Cardiomyopathy, with a decision expected by November 29.
February 05, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BridgeBio Pharma's New Drug Application for Acoramidis has been accepted by the FDA, with an action date set for November 29.
The acceptance of the New Drug Application by the FDA is a positive development for BridgeBio Pharma, indicating progress towards the potential approval of Acoramidis. This could significantly impact the company's product portfolio and future revenue streams, thus likely having a positive effect on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100